194 related articles for article (PubMed ID: 31325667)
1. Acute lethargy after abrupt apomorphine withdrawal in Parkinson's disease.
Cavallieri F; Fraix V; Meoni S; Krack P; Moro E; Castrioto A
J Neurol Sci; 2019 Sep; 404():44-46. PubMed ID: 31325667
[No Abstract] [Full Text] [Related]
2. Loss of Awareness after Continuous Apomorphine Infusion Withdrawal in Parkinson's Disease.
Oliveira V; Videira G; Mendes A
Can J Neurol Sci; 2020 Jul; 47(4):576-577. PubMed ID: 32122433
[No Abstract] [Full Text] [Related]
3. Continuous infusion of apomorphine in patients with advanced Parkinson's disease and different degrees of functional disability.
Salazar G; Martín J; Fragoso M; Font MA
Neurologia; 2017; 32(6):407-410. PubMed ID: 26699210
[No Abstract] [Full Text] [Related]
4. Subcutaneous apomorphine infusion in advanced idiopathic Parkinson's disease and agranulocytosis: a case report.
Condé S; Marques A; Derost P; Debilly B; Lauxerois M; Chanson E; Durif F
Parkinsonism Relat Disord; 2020 Sep; 78():68-69. PubMed ID: 32739839
[No Abstract] [Full Text] [Related]
5. Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study.
Borgemeester RWK; van Laar T
Parkinsonism Relat Disord; 2017 Dec; 45():33-38. PubMed ID: 29032012
[TBL] [Abstract][Full Text] [Related]
6. [Candidate patient for subcutaneous apomorphine injection].
Chacón JR; Mata M
Rev Neurol; 2012; 55 Suppl 1():S7-9. PubMed ID: 23169232
[TBL] [Abstract][Full Text] [Related]
7. Quality of life in Parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort study.
Drapier S; Eusebio A; Degos B; Vérin M; Durif F; Azulay JP; Viallet F; Rouaud T; Moreau C; Defebvre L; Fraix V; Tranchant C; Andre K; Courbon CB; Roze E; Devos D
J Neurol; 2016 Jun; 263(6):1111-9. PubMed ID: 27060084
[TBL] [Abstract][Full Text] [Related]
8. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
Rambour M; Moreau C; Salleron J; Devos D; Kreisler A; Mutez E; Simonin C; Annic A; Dujardin K; Destée A; Defebvre L
Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
[TBL] [Abstract][Full Text] [Related]
9. Effects of increasing doses of apomorphine during stereotaxic neurosurgery in Parkinson's disease: clinical score and internal globus pallidus activity. Short communication.
Stefani A; Stanzione P; Bassi A; Mazzone P; Vangelista T; Bernardi G
J Neural Transm (Vienna); 1997; 104(8-9):895-904. PubMed ID: 9451721
[TBL] [Abstract][Full Text] [Related]
10. Psychiatric and sexual disorders induced by apomorphine in Parkinson's disease.
Courty E; Durif F; Zenut M; Courty P; Lavarenne J
Clin Neuropharmacol; 1997 Apr; 20(2):140-7. PubMed ID: 9099466
[TBL] [Abstract][Full Text] [Related]
11. [Candidate patient for treatment with continuous apomorphine infusion].
Martí MJ; Kulisevsky J
Rev Neurol; 2012; 55 Suppl 1():S15-9. PubMed ID: 23169228
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of apomorphine infusion adverse effects: subcutaneous nodules and neuropsychiatric complications].
Giménez de Béjar V; Carballo-Cordero M
Rev Neurol; 2012; 55 Suppl 1():S25-9. PubMed ID: 23169230
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of subcutaneous apomorphine for the treatment of Parkinson's disease.
Müller T
Expert Opin Pharmacother; 2020 Oct; 21(14):1659-1665. PubMed ID: 32640853
[TBL] [Abstract][Full Text] [Related]
14. [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
Grandas FJ; Sesar-Ignacio Á
Rev Neurol; 2012; 55 Suppl 1():S21-4. PubMed ID: 23169229
[TBL] [Abstract][Full Text] [Related]
15. Sublingual apomorphine: a new pharmacological approach in Parkinson's disease?
Montastruc JL; Rascol O; Senard JM; Houin G; Rascol A
J Neural Transm Suppl; 1995; 45():157-61. PubMed ID: 8748621
[TBL] [Abstract][Full Text] [Related]
16. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
Colzi A; Turner K; Lees AJ
J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
[TBL] [Abstract][Full Text] [Related]
17. Apomorphine therapy in Parkinson's disease: a review.
Haq IU; Lewitt PA; Fernandez HH
Expert Opin Pharmacother; 2007 Nov; 8(16):2799-809. PubMed ID: 17956200
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation rate and long-term adverse events path of apomorphine infusion in advanced Parkinson's disease patients.
Camgrand E; Christine BC; Harroch E; Chouquet C; Barthelemy C; Ory-Magne F; Leung C; Barbosa RP; Rascol O; Fabbri M
Parkinsonism Relat Disord; 2023 Nov; 116():105859. PubMed ID: 37788512
[No Abstract] [Full Text] [Related]
19. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease.
Wenning GK; Bösch S; Luginger E; Wagner M; Poewe W
Adv Neurol; 1999; 80():545-8. PubMed ID: 10410769
[No Abstract] [Full Text] [Related]
20. Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease.
van Laar T; van der Geest R; Danhof M; Boddé HE; Goossens PH; Roos RA
Clin Neuropharmacol; 1998; 21(3):152-8. PubMed ID: 9617506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
